News
Neoadjuvant dd-MVAC improved 5-year overall survival when compared to gemcitabine and cisplatin in a phase 3 trial of patients with MIBC. Neoadjuvant dd-MVAC improved 5-year overall survival when ...
Neoadjuvant dd-MVAC improves overall and disease-specific survival vs gemcitabine-cisplatin in muscle-invasive bladder cancer, a phase 3 trial suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback